EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster Progress in Cancer Care MOST POPULAR Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 ESMO’s Special Consultative Status with United Nations Economic and Social Council... October 10, 2025 Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ June 23, 2020 World Cancer Day 2023: where does the UK stand? February 3, 2023 Load more HOT NEWS What is De-escalation Treatment in Cancer Research? FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... This Common Antibiotic May Help Support Immune System in Cancer Patients...
